Skip to main content
Clinical Trials/NCT01582607
NCT01582607
Unknown
Phase 2

Intrathecal Plain Bupivacaine, Ropivacaine and Levo-bupivacaine With or Without Fentanyl for Elective c Section.

University of Patras1 site in 1 country130 target enrollmentJanuary 2010

Overview

Phase
Phase 2
Intervention
Bupivacaine plain
Conditions
Stillborn Caesarean Section
Sponsor
University of Patras
Enrollment
130
Locations
1
Primary Endpoint
Sensory block
Last Updated
14 years ago

Overview

Brief Summary

The purpose of the investigators study is to compare the clinical effects and side-effects of these three local anaesthetics as sole agents or with the supplementation with fentanyl for c-section, especially when administered in doses achieving approximately an ED 50.

Detailed Description

Intrathecal (i.t.) administration of isobaric bupivacaine, ropivacaine and levobupivacaine with or without addition of fentanyl for c-section do not exist to date . Parturients scheduled for elective caesarean section will be allocated to receive double-blindly i.t. isobaric bupivacaine 10 mg, ropivacaine 15mg , levobupivacaine 10mg or the same local anaesthetics with 10 μg fentanyl respectively. Sensory block (pin prick test) and motor block (Bromage scale) profile, intraoperative and postoperative analgesia, haemodynamics and side effects will be assessed.

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
May 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nikolaos G. Flaris

Anesthesiologist,MD

University of Patras

Eligibility Criteria

Inclusion Criteria

  • Parturients scheduled for elective c section
  • Stillborn
  • Normal cardiotocogram

Exclusion Criteria

  • BMI\>35kg/m2
  • Height \<150cm or \>185cm
  • Age (\<18, \>40)
  • ASA \> II
  • Multiple gestation
  • Pregnancy complications (eclampsia, GDP, placenta previa, \>2 previous c section)
  • Contraindication to spinal anaesthesia
  • Failure to educate the patient, language barrier
  • Patient preferred GA

Arms & Interventions

Group B

subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%

Intervention: Bupivacaine plain

Group R

subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%

Intervention: Ropivacaine plain

Group LB

subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%

Intervention: Levobupivacaine plain

Group RF

subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl

Intervention: ropivacaine plain +. fentanyl

Group BF

subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl

Intervention: bupivacaine plain +fentanyl

Group LBF

subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl

Intervention: Levobupivacaine plain +fentanyl

Outcomes

Primary Outcomes

Sensory block

Time Frame: up to 150 minutes average

sensory block (pin prick test): every 1 min until 30min, every 5 min until 60min. every 10 min until regression to O1 (average 150 minutes)

Motor block

Time Frame: up to 150 minutes

Motor block (Bromage scale): every 1 min until 30min, every 5 min until 60min. every 10 min until complete recovery of motor function (average 150 minutes)

Secondary Outcomes

  • Hemodynamics profile (arterial pressure. heart rate)(up to 150 minutes average)

Study Sites (1)

Loading locations...

Similar Trials